PTX3 and nonpapillary renal cell carcinoma: Patients with low baseline PTX3 levels (<165.0 pg/mL) showed a significantly higher 10-year OS rate as compared with ccRCC patients with high PTX3 serum levels (73.7% vs. 48.4%, p = 0.002) [108].